Patent · US Active

Compounds

US9199980B2 · kind B2 · utility

3Cited by
7References
13Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 5, 2013
Grant dateDec 1, 2015
Priority date
Expiry dateFeb 21, 2034

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K31/439
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compounds of formula (I) described herein are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.